跳至主要内容
临床试验/NCT07762170
NCT07762170招募中4 期

Success Rates and Safety in Managing Spinal and Sacro-Iliac Pain: A Critical Analysis

Igor Wilderman. MD1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2026年7月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
500
试验地点
1
主要终点
Integral of pain relief

研究概览

简要总结

This study aims to analyze the efficacy and safety of different kinds of steroid injections for back pain, comparing different steroids, dosages, locations (epidural, facet joints, nerve blocks), and also the difference between injections with steroids and local anesthetics, to optimize this treatment that is currently not standardized. The investigators will compare retrospectively and prospectively the efficacy of different injections in the same patients, using mainly a parameter called integral of pain relief, which combines the percentage of pain relief provided by a treatment and its duration over time, as well as improvements in functionality.

详细描述

This single-centre study will consist of two parts, one retrospective and one prospective with cross-over design, to analyze and summarize the investigators' experience in the evaluation of:

  • Efficacy of ultrasonography (US)-guided epidural steroid injections (caudal and interlaminar, compared to transforaminal if performed elsewhere and data available) in patients with lumbar-sacral pain for central spinal stenosis, neuroforaminal stenosis, herniated disc, or failed back surgery syndrome (FBSS);
  • Efficacy of cervical, thoracic, and lumbar facet joint and sacroiliac joints (SIJ) injections in patients with nociceptive spinal pain (e.g., osteoarthritis [OA]);
  • Spinal levels most frequently affected;
  • How frequently a pain presenting as sciatica is actually due instead to hip OA, trochanter pain, bursitis, or SIJ pain, rather than spine pathology.

In this study, the investigators will include at least 100 patients per part with lumbar spinal pain due to lumbar canal stenosis, herniated discs or FBSS (lumbar radiculopathy), treated with caudal or interlaminar epidural steroid injections through different protocols, all under US guidance. In addition, the investigators will examine different administration protocols, including the following injections: facet joints (100 each for cervical and lumbar pain, and as many as possible for thoracic) and/or SIJ (100), compared with injections of local anesthetics only, with Marcaine or Sensorcaine (bupivacaine) or Xylocaine (lidocaine), or oral low-dose naltrexone (spinal radiculopathy).

Comparing these interventions through rigorous research, the study may provide healthcare professionals with refined treatment guidelines, optimized patient care pathways, and ultimately improve outcomes and quality of life for individuals living with chronic back pain. This research could benefit current patients and contribute to the broader knowledge in pain management, guiding future advancements in the field.

The primary objectives of this study are to determine:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •>18 years of age;
  • •Diagnosis of lumbar, cervical, or thoracic pain with various etiologies;
  • •Eligibility to receive steroid injections for back pain, including epidural, facet joints, or SIJ injections, or other injections (e.g., local anesthetics);
  • •Being willing and able to provide NRS pain ratings and PROMIS functionality ratings before the intervention, and the same scores plus IPR, fIPR, and PGIC at various follow-up points after the intervention;
  • •Provide written informed consent.

排除标准

  • •Diagnosis of dementia, Parkinson's disease or other cognitive impairments;
  • •Congenital or acquired polyneuropathy;
  • •Back surgery in the month before injection treatment or planned surgery in the subsequent 3 months;
  • •Any clinically significant acute or chronic medical condition that in the judgment of Investigator may preclude injection in the epidural space or compromise patient safety, limit patient's ability to complete the study, and/or compromise the objectives of the study;
  • •Participation in any other competing clinical study within 3 months prior to screening and during the study period.

研究组 & 干预措施

Spinal steroid injections with triamcinolone

Active Comparator

干预措施: triamcinolone acetonide (Kenalog) (Drug)

Spinal steroid injections with methylprednisolone

Active Comparator

干预措施: Depo-Medrol 40Mg/Ml Suspension for Injection (Drug)

Spinal steroid injections with betamethasone

Active Comparator

干预措施: Celestone Soluspan 6Mg/Ml Suspension for Injection (Drug)

Spinal steroid injections with dexamethasone

Active Comparator

干预措施: Dexamethasone (Drug)

结局指标

主要结局

Integral of pain relief

时间窗: 8-12 weeks, up to 6 months or one year if applicable

parameter obtained by multiplying the percentage of pain relief provided by a treatment by the number of days of relief

Numeric rating scale

时间窗: 2, 4, 6, 8, 12 weeks

Scale from 0 to 10 assessing the pain intensity

Functional integral of pain relief

时间窗: 8-12 weeks, up to 6 months or one year if applicable

Percentage of functionality improvements multiplied by the number of days of improvement duration

Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire - custom version

时间窗: 2, 4, 6, 8, 12 weeks

Customized PROMIS questionnaire to assess the overall functional status: 12 questions, each with scores variable between 5 (no difficulty or best possible situation, depending on the question ) and 1 (unable to do or worst case scenario). Four questions relate to physical function, two to fatigue, one to sleep quality, two to mood, two to social roles and activity, and one to pain interference with general activities. The maximum score (no problem) is 60, and the minimum is 12 (severely incapacitated).

Patient's global impression of change (PGIC)

时间窗: 2, 4, 6, 8, 12 weeks

7-grade scale representing the overall assessment of change perceived by the patient, from Very Much Improved to Very Much Worsened

次要结局

未报告次要终点

研究者

发起方
Igor Wilderman. MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Igor Wilderman. MD

Principal Investigator

Wilderman Medical Clinic

研究点 (1)

Loading locations...

相似试验